Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 23;3(3):e166–e175. doi: 10.1016/S2666-7568(22)00012-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Antibody responses to homologous versus heterologous use of mRNA vaccines based on previous infection status

Antibody responses to the receptor-binding domain (RBD) of the spike protein, the spike protein, and the nucleocapsid protein, with homologous versus heterologous use of mRNA vaccines, based on the absence (A) or presence (B) of previous SARS-CoV-2 infection. Homologous vaccination consisted of both doses being either mRNA-1273 or BNT162b2, whereas heterologous vaccination consisted of mRNA-1273 followed by BNT162b2. Medians are indicated by diamonds, the IQR values are indicated by horizontal segments, and saturation thresholds are indicated by dashed lines. t1=before first dose. t2=approximately 4 weeks after first dose. t3=6–10 weeks after first dose. t4=up to 2 days before administration of second dose (16 weeks after prime dose). t5=4 weeks after second dose.